Camella leverages her deep technical expertise to invest in and support bold entrepreneurs in the Life Sciences and Healthcare sectors.
Before joining OCV, Dr. Wilson worked at the Boston Consulting Group supporting global Biopharma and CPG clients in achieving their strategic and operational goals. As a Postdoctoral Fellow at UCSF, her research focused on uncovering mechanisms of lipid accumulation and inflammation in NAFLD and NASH and on developing novel therapies for improving insulin sensitivity. She also supported early-stage catalytic investments and business development efforts for the USCF-CTSI Catalyst Program. Her doctoral thesis was centered on utilizing genetic models to characterize a novel pancreas-derived peptide and its role in hepatic glucose production.
Camella holds a Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and a B.Sc. in Biochemistry from Temple University. She is a native of St. Vincent & the Grenadines.